Skip to main content

Table 1 Patient characteristics and clinicopathological features of tumors

From: Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology

 Breast cancer primaries with ophthalmic metastasis identified through TIES (absolute number + percentage)
N = 28
Metastatic breast cancer in the UPMC Network Cancer Registry (absolute number + percentage)
N = 1366
p value
Age
 Median age at diagnosis of primary55530.4455
 < 50 at diagnosis10 (35.7%)520 (38.1%)0.847
 ≥ 50 at diagnosis18 (64.3%)846 (61.9%) 
Race  1
 White26 (92.9%)1248 (91.4%) 
 Black2 (7.1%)104 (7.6%) 
 Others014 (1.0%) 
Survival (median in month)
 Overall survival82.158.80.47
 Disease-free survival26.435.40.52
 Distant metastasis-free survival34.236.60.76
Histological subtypes  0.00067
 IDC14 (50.0%)1167 (85.4%) 
 ILC9 (32.1%)155 (11.3%) 
 Mixed2 (7.1%)44 (3.2%) 
 Unknown3 (10.7%)0 
Stage  0.00106
 Stage 0 11 (0.8%) 
 Stage I0 (0%)340 (24.9%) 
 Stage II5 (17.9%)573 (41.9%) 
 Stage III7 (25.0%)186 (13.6%) 
 Stage IV7 (25.0%)184 (13.5%) 
 Stage unknown9 (32.1%)72 (5.3%) 
Lymph node status  0.04927
 Positive18 (64.3%)814 (59.6%) 
 Negative2 (7.1%)386 (28.3%) 
 Unknown8 (28.6%)166 (12.2%) 
ER status  0.2597
 ER+21 (75.0%)981 (71.8%) 
 ER−4 (14.3%)385 (28.2%) 
 Unknown3 (10.7%)0 
PR status  0.2809
 PR+17 (60.7%)805 (58.9%) 
 PR−6 (21.4%)519 (38.0%) 
 PR unknown5 (17.9%)42 (3.1%) 
HER2 status  1
 HER2/neu +3 (10.7%)51 (3.7%) 
 HER2/neu −20 (71.4%)277 (20.3%) 
 Equivocal09 (0.7%) 
 HER2/neu unknown5 (17.9%)1029 (75.3%) 
  1. IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, HER2/neu human epidermal growth factor receptor